Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva By Zhizi Zhao, 12th December 2017
Clementia Reports Third Quarter 2017 Financial Results and Business Highlights By Zhizi Zhao, 13th November 2017
Clementia Pharmaceuticals to Participate in Upcoming Investor Conferences By Zhizi Zhao, 6th September 2017
Clementia Announces Data Presentations at Upcoming Medical Conferences in September By Zhizi Zhao, 31st August 2017
Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering By Zhizi Zhao, 21st August 2017
Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends By Zhizi Zhao, 28th March 2017
Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva By Zhizi Zhao, 14th October 2016
Positive Effects of Palovarotene on Spontaneous Heterotopic Ossification, Mobility, and Skeletal Growth in Mouse Models of FOP Reported in Journal of Bone and Mineral Research By Zhizi Zhao, 14th April 2016